Showing 7941-7950 of 8696 results for "".
- CeraVe Launches Hyaluronic Acid Serum, Line of Products for Diabetic Skinhttps://practicaldermatology.com/news/cerave-launches-hyaluronic-acid-serum-line-of-products-for-diabetic-skin/2457497/L'Oréal’s CeraVe is rolling out a Hydrating Hyaluronic Acid Serum and a Diabetics' Dry Skin Relief line, which includes a Moisturizing Cream, Hand and Foot Cream and a Cleansing Wash. Hitting shelves in late 2018, the Diabetics'
- Candela, VBF Provide Laser Treatments to Families Including a Special Toddlerhttps://practicaldermatology.com/news/candela-vbf-provide-laser-treatments-to-families-including-a-special-toddler/2457498/
- Case Study: Allergy Shots May Treat Severe Eczemahttps://practicaldermatology.com/news/case-study-allergy-shots-may-treat-severe-eczema/2457503/Allergy shots provided significant benefits to the eczema symptoms of a 48-year-old man, according to challenging case presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Seattle. “The man had suffered with severe eczema since chi
- MDsave Partners with CareCredithttps://practicaldermatology.com/news/mdsave-partners-with-carecredit/2457505/MDsave is partnering with CareCredit to bring easy healthcare financing to their mission of providing better cost transparency to patients. As consumers face ever increasing healthcare costs, CareCredit, a Synchrony solution, offers patients the ability to pay over time for deductibles, co-pays,
- Study Highlights Unique Characteristics of Melanoma Patients Who Use Tanning Bedshttps://practicaldermatology.com/news/study-highlights-unique-characteristics-of-melanoma-patients-who-use-tanning-beds/2457509/Younger individuals and females are more likely to use tanning beds, and as a result they tend to develop melanoma earlier, according to
- The American Dermatological Association Is On Board with American Cancer Society's HPV Vaccine Policyhttps://practicaldermatology.com/news/the-american-dermatological-association-is-on-board-with-american-cancer-societys-hpv-vaccine-policy/2457513/The American Dermatological Association is co-sponsoring the American Cancer Society’s public policy of vaccination against Human Papillomavirus infections [HPV] beginning at age 11 or 12 for girls and boys. HPV is associated with protean medical illne
- Endo's CCH Improves Appearance of Cellulite in Buttockshttps://practicaldermatology.com/news/endos-cch-improves-appearance-of-cellulite-in-buttocks/2457516/Endo International plc’s clostridium histolyticum (CCH) performed well in two identical Phase 3 studies for the treatment of cellulite in the buttocks. Subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment,
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- FDA Approves Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-lyft-for-midface-injection-via-cannula/2457518/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the second ca
- Mayne Pharma Acquires FDA-approved Halobetasol Foamhttps://practicaldermatology.com/news/mayne-pharma-acquires-fda-approved-halobetasol-foam/2457520/Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for an investment of up to $32 million (comprising $10 million in cash up front, $5 million at commercial launch plus continge